RedHill Biopharma develops medicines for gastrointestinal and infectious diseases, promoting drugs like Talicia for H. pylori infections and Aemcolo for travelers’ diarrhea. Their late-stage programs include RHB-204, opaganib, RHB-107, RHB-104, and RHB-102.
RDHL has been in the news recently: Bristol-Myers Squibb & Co. is projected to report second-quarter 2025 earnings of $1.585 per share and sales of $11.31 billion on July 31. Additionally, a TriNetX survey shows that while 77% of pharma companies utilize real-world data in drug development, they encounter challenges related to data compatibility and regulatory issues.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
